{"id":60585,"date":"2025-01-07T07:05:56","date_gmt":"2025-01-07T06:05:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/acellera-therapeutics-unveils-aceforce-1-0-a-novel-family-of-next-generation-neural-network-potential-accelerating-drug-discovery\/"},"modified":"2025-01-07T07:05:56","modified_gmt":"2025-01-07T06:05:56","slug":"acellera-therapeutics-unveils-aceforce-1-0-a-novel-family-of-next-generation-neural-network-potential-accelerating-drug-discovery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/acellera-therapeutics-unveils-aceforce-1-0-a-novel-family-of-next-generation-neural-network-potential-accelerating-drug-discovery\/","title":{"rendered":"Acellera Therapeutics Unveils AceForce 1.0: A Novel Family of Next-Generation Neural Network Potential Accelerating Drug Discovery"},"content":{"rendered":"
\n

FREMONT, Calif.–(BUSINESS WIRE)–Acellera Therapeutics<\/a>, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of AceForce 1.0<\/b><\/a>, its groundbreaking neural network potential (NNP) model designed to deliver quantum-level accuracy for predicting atomic interactions\u2014an essential factor in identifying promising drug candidates earlier and more efficiently.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cAceForce 1.0 marks a major leap forward by bringing quantum-like accuracy into everyday drug discovery workflows<\/i>,\u201d said Gianni De Fabritiis<\/a>, Founder and Chief Executive Officer of Acellera Therapeutics. \u201cEven in this initial release, AceForce 1.0 matches or surpasses state-of-the-art molecular potentials developed over decades. As we expand our training sets, speed up calculations, and refine these AI-driven models, we look forward to empowering scientists to identify promising molecules more quickly, reliably, and affordably<\/i>.\u201d<\/p>\n

\nKey Highlights of AceForce 1.0<\/b><\/p>\n